首页 > 最新文献

Clinical Drug Investigation最新文献

英文 中文
Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the context of Anti-Cancer Therapy: a Multidisciplinary Viewpoint by Portuguese Experts. 抗癌治疗中药物诱发间质性肺病的诊断和管理:葡萄牙专家的多学科观点。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-05 DOI: 10.1007/s40261-024-01400-z
Mário Fontes E Sousa, Sérgio Campainha, Inês Dias Marques, Rui Dinis, João Rodrigues Inácio, João João Mendes, Rita Luís, Ana Magalhães Ferreira, Ricardo Racha-Pacheco, Rui Rolo, Gabriela Sousa, Paulo Cortes

Drug-induced interstitial lung disease (DI-ILD) is a significant complication in patients undergoing treatment with certain anti-cancer therapies, with incidence rates rising, particularly with newer drugs such as trastuzumab-deruxtecan, which may impact their safe and effective use. Although the exact pathophysiological mechanisms remain unknown, and different drugs may induce lung damage through different pathways, the most recognized mechanisms are cytotoxic- and immune-mediated effects. Multidisciplinary teams play a crucial role in the diagnosis, management, and prevention of DI-ILD. Given the wide variability in the onset of DI-ILD, which may occur within the first few days of treatment or months after, patient education and clinician training are essential for early detection and improved outcomes. Moreover, the diagnostic confirmation requires the exclusion of alternative causes through clinical, imaging and bronchoscopy evaluation. Treatment strategies largely depend on the grade of severity of the clinical manifestations of DI-ILD, ranging from interruption or discontinuation of the offending drug to corticosteroid therapy and hospitalization for appropriate monitoring. Nonetheless, further research is needed to better understand the impact of emerging anti-cancer drugs on DI-ILD and to establish standardized management protocols.

药物诱发间质性肺病(DI-ILD)是接受某些抗癌疗法治疗的患者的一个重要并发症,其发病率不断上升,尤其是曲妥珠单抗-德鲁司坦等新药,这可能会影响其安全有效的使用。尽管确切的病理生理学机制尚不清楚,而且不同的药物可能通过不同的途径诱发肺损伤,但最公认的机制是细胞毒性和免疫介导效应。多学科团队在 DI-ILD 的诊断、管理和预防中发挥着至关重要的作用。鉴于 DI-ILD 的发病差异很大,可能发生在治疗的头几天或几个月后,因此患者教育和临床医生培训对于早期发现和改善预后至关重要。此外,确诊需要通过临床、影像学和支气管镜评估排除其他病因。治疗策略主要取决于 DI-ILD 临床表现的严重程度,包括中断或停用违规药物、皮质类固醇治疗和住院进行适当监测。然而,要更好地了解新出现的抗癌药物对DI-ILD的影响并制定标准化的治疗方案,还需要进一步的研究。
{"title":"Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the context of Anti-Cancer Therapy: a Multidisciplinary Viewpoint by Portuguese Experts.","authors":"Mário Fontes E Sousa, Sérgio Campainha, Inês Dias Marques, Rui Dinis, João Rodrigues Inácio, João João Mendes, Rita Luís, Ana Magalhães Ferreira, Ricardo Racha-Pacheco, Rui Rolo, Gabriela Sousa, Paulo Cortes","doi":"10.1007/s40261-024-01400-z","DOIUrl":"https://doi.org/10.1007/s40261-024-01400-z","url":null,"abstract":"<p><p>Drug-induced interstitial lung disease (DI-ILD) is a significant complication in patients undergoing treatment with certain anti-cancer therapies, with incidence rates rising, particularly with newer drugs such as trastuzumab-deruxtecan, which may impact their safe and effective use. Although the exact pathophysiological mechanisms remain unknown, and different drugs may induce lung damage through different pathways, the most recognized mechanisms are cytotoxic- and immune-mediated effects. Multidisciplinary teams play a crucial role in the diagnosis, management, and prevention of DI-ILD. Given the wide variability in the onset of DI-ILD, which may occur within the first few days of treatment or months after, patient education and clinician training are essential for early detection and improved outcomes. Moreover, the diagnostic confirmation requires the exclusion of alternative causes through clinical, imaging and bronchoscopy evaluation. Treatment strategies largely depend on the grade of severity of the clinical manifestations of DI-ILD, ranging from interruption or discontinuation of the offending drug to corticosteroid therapy and hospitalization for appropriate monitoring. Nonetheless, further research is needed to better understand the impact of emerging anti-cancer drugs on DI-ILD and to establish standardized management protocols.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers. 新型髓过氧化物酶抑制剂米替司他在日本和中国健康志愿者中的药代动力学和耐受性研究
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-04 DOI: 10.1007/s40261-024-01402-x
Mikael Sunnåker, Chandrali Bhattacharya, Karin Nelander, Malin Aurell, Maria Heijer, Anna Collén, David Han, Julie Holden, Monika Trebski, Pavlo Garkaviy, Hans Ericsson

Background and objective: Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis and chronic obstructive pulmonary disease. This study evaluated the pharmacokinetics, safety and tolerability of multiple ascending doses of mitiperstat in healthy male Japanese and Chinese volunteers.

Methods: Three cohorts of eight Japanese participants were randomized to receive once-daily oral doses of mitiperstat 2.5, 5 or 10 mg or matching placebo for 10 days (six receiving mitiperstat and two receiving placebo, per cohort). One cohort of eight Chinese participants was randomized to receive mitiperstat 5 mg or matching placebo for 10 days (six receiving mitiperstat and two receiving placebo).

Results: Mitiperstat was rapidly absorbed, with a time to maximum plasma concentration of 1-2 h. Exposure was dose proportional over the investigated dose range, as assessed by area under the concentration-time curve and maximum and trough plasma concentrations. Steady state was reached within 10 days, and accumulation was observed, consistent with the observed long elimination half-life of mitiperstat (50.2-57.8 h). Except for a few events of maculopapular rash, mitiperstat up to 5 mg was well tolerated in participants of Japanese or Chinese origin.

Conclusions: The pharmacokinetics of mitiperstat were similar among Japanese and Chinese participants. These characteristics were similar to those in a previous multiple ascending-dose study in healthy primarily white and Black/African American volunteers. Therefore, the pharmacokinetics of mitiperstat do not affect dosing regimens in these different populations.

Trial registration: NCT04232345 (03/01/2020).

背景和目的米替哌司他(AZD4831)是一种新型不可逆口服髓过氧化物酶抑制剂,目前正处于临床开发阶段,可用于治疗射血分数保留型心力衰竭、代谢功能障碍相关性脂肪性肝炎和慢性阻塞性肺病。本研究评估了日本和中国健康男性志愿者服用多个升剂量米替哌司坦的药代动力学、安全性和耐受性:三个队列的八名日本参与者被随机分配接受每日一次口服剂量为 2.5、5 或 10 毫克的米替司特或相应的安慰剂,为期 10 天(每个队列六人接受米替司特,两人接受安慰剂)。一个由8名中国参与者组成的队列随机接受米替哌司坦5毫克或相应安慰剂,为期10天(6人接受米替哌司坦,2人接受安慰剂):米哌司坦吸收迅速,血浆浓度达到最大值的时间为1-2小时。在研究的剂量范围内,米哌司坦的暴露与剂量成正比,浓度-时间曲线下面积以及血浆浓度的最大值和谷值均可评估这一点。米替哌司坦在 10 天内达到稳定状态,并出现蓄积现象,这与观察到的米替哌司坦的长消除半衰期(50.2-57.8 小时)一致。除了少数斑丘疹外,日本或中国血统的参试者对5毫克以下的米替司他耐受性良好:结论:日本人和中国人服用米替司他的药代动力学相似。结论:日本和中国参试者的药代动力学相似,这些特征与之前在主要为白人和黑人/非洲裔美国人的健康志愿者中进行的多次递增剂量研究相似。因此,米替哌司坦的药代动力学不会影响这些不同人群的给药方案:NCT04232345 (03/01/2020).
{"title":"Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.","authors":"Mikael Sunnåker, Chandrali Bhattacharya, Karin Nelander, Malin Aurell, Maria Heijer, Anna Collén, David Han, Julie Holden, Monika Trebski, Pavlo Garkaviy, Hans Ericsson","doi":"10.1007/s40261-024-01402-x","DOIUrl":"https://doi.org/10.1007/s40261-024-01402-x","url":null,"abstract":"<p><strong>Background and objective: </strong>Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis and chronic obstructive pulmonary disease. This study evaluated the pharmacokinetics, safety and tolerability of multiple ascending doses of mitiperstat in healthy male Japanese and Chinese volunteers.</p><p><strong>Methods: </strong>Three cohorts of eight Japanese participants were randomized to receive once-daily oral doses of mitiperstat 2.5, 5 or 10 mg or matching placebo for 10 days (six receiving mitiperstat and two receiving placebo, per cohort). One cohort of eight Chinese participants was randomized to receive mitiperstat 5 mg or matching placebo for 10 days (six receiving mitiperstat and two receiving placebo).</p><p><strong>Results: </strong>Mitiperstat was rapidly absorbed, with a time to maximum plasma concentration of 1-2 h. Exposure was dose proportional over the investigated dose range, as assessed by area under the concentration-time curve and maximum and trough plasma concentrations. Steady state was reached within 10 days, and accumulation was observed, consistent with the observed long elimination half-life of mitiperstat (50.2-57.8 h). Except for a few events of maculopapular rash, mitiperstat up to 5 mg was well tolerated in participants of Japanese or Chinese origin.</p><p><strong>Conclusions: </strong>The pharmacokinetics of mitiperstat were similar among Japanese and Chinese participants. These characteristics were similar to those in a previous multiple ascending-dose study in healthy primarily white and Black/African American volunteers. Therefore, the pharmacokinetics of mitiperstat do not affect dosing regimens in these different populations.</p><p><strong>Trial registration: </strong>NCT04232345 (03/01/2020).</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus. 2型糖尿病患者每周一次服用伊科达克胰岛素和赛马鲁肽固定比例复方制剂的药代动力学特性与单独服用每种成分的药代动力学特性的比较。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-03 DOI: 10.1007/s40261-024-01405-8
Lisbet Westergaard, Lene Alifrangis, Stephen T Buckley, Hans Veit Coester, Thomas Klitgaard, Niels R Kristensen, Erica Nishimura, Lea Nørgreen, Thaís M P Rocha, Dorte B Steensgaard, Andreas Vegge, Leona Plum-Mörschel

Background and objective: IcoSema is being developed as a subcutaneous once-weekly fixed-ratio combination of the once-weekly basal insulin icodec and the once-weekly glucagon-like peptide-1 receptor agonist semaglutide. This study investigated the pharmacokinetics of icodec and semaglutide in IcoSema versus separate administration of each component in individuals with type 2 diabetes mellitus (T2DM).

Methods: In a randomised, double-blind, three-period crossover study, 31 individuals with T2DM (18-64 years, body weight 80-120 kg, glycosylated haemoglobin 6.0-8.5%) received single subcutaneous injections of IcoSema (175 U icodec, 0.5 mg semaglutide), icodec (175 U) or semaglutide (0.5 mg) with 6-9 weeks' washout. Pharmacokinetic blood samples were drawn up to 840 h post-dose.

Results: Icodec pharmacokinetics were unaffected by combining icodec with semaglutide. The 90% confidence interval (CI) of IcoSema/icodec was within 0.80-1.25 for total exposure (area under the curve from zero to last quantifiable observation; AUC0-t: ratio [90% CI] 1.06 [1.01; 1.12]) and maximum concentration (Cmax): 1.12 [1.06; 1.18]. Semaglutide AUC0-t was also unaffected by combination with icodec (IcoSema/semaglutide 1.11 [1.05; 1.17]). However, semaglutide Cmax was higher for IcoSema versus semaglutide alone (IcoSema/semaglutide 1.99 [1.84; 2.15]) and occurred earlier for IcoSema (12 versus 84 h). Results of in vitro albumin binding studies and animal pharmacokinetic studies supported that the change in semaglutide absorption pharmacokinetics in IcoSema is owing to competition for albumin binding locally at the injection site with icodec outcompeting semaglutide. IcoSema, icodec and semaglutide were well-tolerated, although more gastrointestinal related adverse events occurred with IcoSema versus icodec or semaglutide alone.

Conclusion: The combination of icodec and semaglutide in IcoSema leads to a higher and earlier maximum semaglutide concentration, which will guide the dose recommendations for IcoSema.

Clinical trial: ClinicalTrials.gov identifier: NCT03789578.

背景和目的IcoSema是每周一次的基础胰岛素icodec和每周一次的胰高血糖素样肽-1受体激动剂semaglutide的皮下固定比例复方制剂。本研究调查了伊科赛马中的icodec和semaglutide在2型糖尿病(T2DM)患者中的药代动力学,以及每种成分单独给药的药代动力学:在一项随机、双盲、三期交叉研究中,31 名 T2DM 患者(18-64 岁,体重 80-120 公斤,糖化血红蛋白 6.0-8.5%)接受了 IcoSema(175 U icodec、0.5 毫克 semaglutide)、icodec(175 U)或 semaglutide(0.5 毫克)的单次皮下注射,并进行了 6-9 周的冲洗。药代动力学血样在服药后840小时内采集:结果:icodec与semaglutide合用不会影响icodec的药代动力学。在总暴露量(从零到最后一次可量化观察的曲线下面积;AUC0-t:比值[90% CI] 1.06 [1.01; 1.12])和最大浓度(Cmax)方面,伊科塞马/伊科代克的 90% 置信区间(CI)在 0.80-1.25 之间:1.12 [1.06; 1.18].塞马鲁肽的AUC0-t也不受与icodec联用的影响(IcoSema/塞马鲁肽:1.11 [1.05; 1.17])。不过,与单独使用塞马鲁肽相比,伊科司马的塞马鲁肽Cmax更高(伊科司马/塞马鲁肽为1.99 [1.84; 2.15]),而且伊科司马的Cmax出现得更早(12小时对84小时)。体外白蛋白结合研究和动物药代动力学研究的结果表明,IcoSema 中塞马鲁肽吸收药代动力学的变化是由于注射部位的白蛋白结合竞争导致的,icodec 优于塞马鲁肽。IcoSema、icodec和semaglutide的耐受性良好,但IcoSema与icodec或单独使用semaglutide相比,发生了更多的胃肠道相关不良事件:结论:在IcoSema中联合使用icodec和semaglutide可提高并提前达到semaglutide的最大浓度,这将为IcoSema的剂量推荐提供指导:临床试验:ClinicalTrials.gov identifier:NCT03789578。
{"title":"Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus.","authors":"Lisbet Westergaard, Lene Alifrangis, Stephen T Buckley, Hans Veit Coester, Thomas Klitgaard, Niels R Kristensen, Erica Nishimura, Lea Nørgreen, Thaís M P Rocha, Dorte B Steensgaard, Andreas Vegge, Leona Plum-Mörschel","doi":"10.1007/s40261-024-01405-8","DOIUrl":"https://doi.org/10.1007/s40261-024-01405-8","url":null,"abstract":"<p><strong>Background and objective: </strong>IcoSema is being developed as a subcutaneous once-weekly fixed-ratio combination of the once-weekly basal insulin icodec and the once-weekly glucagon-like peptide-1 receptor agonist semaglutide. This study investigated the pharmacokinetics of icodec and semaglutide in IcoSema versus separate administration of each component in individuals with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>In a randomised, double-blind, three-period crossover study, 31 individuals with T2DM (18-64 years, body weight 80-120 kg, glycosylated haemoglobin 6.0-8.5%) received single subcutaneous injections of IcoSema (175 U icodec, 0.5 mg semaglutide), icodec (175 U) or semaglutide (0.5 mg) with 6-9 weeks' washout. Pharmacokinetic blood samples were drawn up to 840 h post-dose.</p><p><strong>Results: </strong>Icodec pharmacokinetics were unaffected by combining icodec with semaglutide. The 90% confidence interval (CI) of IcoSema/icodec was within 0.80-1.25 for total exposure (area under the curve from zero to last quantifiable observation; AUC<sub>0-t</sub>: ratio [90% CI] 1.06 [1.01; 1.12]) and maximum concentration (C<sub>max</sub>): 1.12 [1.06; 1.18]. Semaglutide AUC<sub>0-t</sub> was also unaffected by combination with icodec (IcoSema/semaglutide 1.11 [1.05; 1.17]). However, semaglutide C<sub>max</sub> was higher for IcoSema versus semaglutide alone (IcoSema/semaglutide 1.99 [1.84; 2.15]) and occurred earlier for IcoSema (12 versus 84 h). Results of in vitro albumin binding studies and animal pharmacokinetic studies supported that the change in semaglutide absorption pharmacokinetics in IcoSema is owing to competition for albumin binding locally at the injection site with icodec outcompeting semaglutide. IcoSema, icodec and semaglutide were well-tolerated, although more gastrointestinal related adverse events occurred with IcoSema versus icodec or semaglutide alone.</p><p><strong>Conclusion: </strong>The combination of icodec and semaglutide in IcoSema leads to a higher and earlier maximum semaglutide concentration, which will guide the dose recommendations for IcoSema.</p><p><strong>Clinical trial: </strong>ClinicalTrials.gov identifier: NCT03789578.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome. 中度至重度腹泻为主的肠易激综合征患者短期服用利福昔明 2200 毫克/天对腹部症状的疗效及其对生活质量的影响的试验性研究》。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-30 DOI: 10.1007/s40261-024-01403-w
Marjan Mokhtare, Maryam Fathi, Amir M Sadeghian, Mohammad-Javad Sotoudeheian, Abolfazl Namazi

Background and objective: Rifaximin is used to treat diarrhea-predominant irritable bowel syndrome (IBS-D). However, determining the most effective regimen remains a challenge. This study aimed to evaluate the effectiveness and safety of a 10-day high-dose course of rifaximin (2200 mg/day) and its effects on both abdominal symptoms and quality of life (QOL) in patients with IBS-D.

Method: Adult patients with moderate to severe IBS-D (Rome IV) and fecal urgency and bloating were prescribed rifaximin 1100 mg twice daily for 10 days. Demographic information, the IBS Symptom Severity Index (IBS-SSI) score (using a 7-point Likert scale), and Bristol Stool Scale (BSS) score were recorded at baseline, day 10, and 4 weeks after treatment cessation. IBS Symptom Severity Score (IBS-SSS) and IBS-QOL scores were recorded at baseline and day 10. Any drug adverse effects were recorded.

Results: In total, 39 patients completed the study. Average scores for all abdominal symptoms and BSS showed significant improvement at day 10 and 4 weeks after treatment cessation (all p < 0.001). A significant improvement was seen in IBS-SSS and overall IBS-QOL score at day 10 (p < 0.001), with the highest improvement (31%) in interference with activity. Moreover, composite improvement rates were 38.64% for all abdominal symptoms, together with BSS < 5, bi-composite (66.67% for abdominal pain + bloating; 61.54% for abdominal pain + urgency), and 56.41% for tri-composite (abdominal pain + bloating + urgency) symptoms. Notably, no serious adverse effects were reported, and the adherence rate was 94.9%.

Conclusions: Abdominal symptoms and overall QOL, especially in social and work dimensions, significantly improved in patients with moderate to severe IBS-D following a regimen of rifaximin 2200 mg/day, which was well tolerated.

背景和目的:利福昔明用于治疗以腹泻为主的肠易激综合征(IBS-D)。然而,确定最有效的治疗方案仍是一项挑战。本研究旨在评估利福昔明 10 天大剂量疗程(2200 毫克/天)的有效性、安全性及其对 IBS-D 患者腹部症状和生活质量(QOL)的影响:方法:对患有中度至重度肠易激综合征(IBS-D)(罗马Ⅳ型)、便急和腹胀的成人患者处方利福昔明,剂量为 1100 毫克,每天两次,疗程为 10 天。在基线、第 10 天和停止治疗 4 周后记录人口统计学信息、肠易激综合征症状严重程度指数 (IBS-SSI) 评分(采用 7 点李克特量表)和布里斯托粪便量表 (BSS) 评分。在基线和第 10 天记录肠易激综合征症状严重程度评分(IBS-SSS)和肠易激综合征-QOL 评分。记录任何药物不良反应:共有 39 名患者完成了研究。所有腹部症状和 BSS 的平均得分在第 10 天和停止治疗 4 周后均有明显改善(均为 p 结论:所有腹部症状和总体 QOL 均有明显改善:中度至重度肠易激综合征(IBS-D)患者在服用利福昔明 2200 毫克/天治疗方案后,腹部症状和总体 QOL(尤其是社交和工作方面)明显改善,且耐受性良好。
{"title":"A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome.","authors":"Marjan Mokhtare, Maryam Fathi, Amir M Sadeghian, Mohammad-Javad Sotoudeheian, Abolfazl Namazi","doi":"10.1007/s40261-024-01403-w","DOIUrl":"https://doi.org/10.1007/s40261-024-01403-w","url":null,"abstract":"<p><strong>Background and objective: </strong>Rifaximin is used to treat diarrhea-predominant irritable bowel syndrome (IBS-D). However, determining the most effective regimen remains a challenge. This study aimed to evaluate the effectiveness and safety of a 10-day high-dose course of rifaximin (2200 mg/day) and its effects on both abdominal symptoms and quality of life (QOL) in patients with IBS-D.</p><p><strong>Method: </strong>Adult patients with moderate to severe IBS-D (Rome IV) and fecal urgency and bloating were prescribed rifaximin 1100 mg twice daily for 10 days. Demographic information, the IBS Symptom Severity Index (IBS-SSI) score (using a 7-point Likert scale), and Bristol Stool Scale (BSS) score were recorded at baseline, day 10, and 4 weeks after treatment cessation. IBS Symptom Severity Score (IBS-SSS) and IBS-QOL scores were recorded at baseline and day 10. Any drug adverse effects were recorded.</p><p><strong>Results: </strong>In total, 39 patients completed the study. Average scores for all abdominal symptoms and BSS showed significant improvement at day 10 and 4 weeks after treatment cessation (all p < 0.001). A significant improvement was seen in IBS-SSS and overall IBS-QOL score at day 10 (p < 0.001), with the highest improvement (31%) in interference with activity. Moreover, composite improvement rates were 38.64% for all abdominal symptoms, together with BSS < 5, bi-composite (66.67% for abdominal pain + bloating; 61.54% for abdominal pain + urgency), and 56.41% for tri-composite (abdominal pain + bloating + urgency) symptoms. Notably, no serious adverse effects were reported, and the adherence rate was 94.9%.</p><p><strong>Conclusions: </strong>Abdominal symptoms and overall QOL, especially in social and work dimensions, significantly improved in patients with moderate to severe IBS-D following a regimen of rifaximin 2200 mg/day, which was well tolerated.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study. 多发性硬化症患者使用富马酸双嘧达莫的实际体验:一项前瞻性多中心研究。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-28 DOI: 10.1007/s40261-024-01397-5
Clara Aguirre, Ana Alonso-Torres, Eduardo Agüera, José Manuel García-Domínguez, Paloma Montero-Escribano, Vicente González-Quintanilla, Lucienne Costa-Frossard, Celia Oreja-Guevara, Virginia Reyes-Garrido, Ana Belén Caminero-Rodríguez, Javier Riancho, Octavio Sánchez, Lucía Forero, Fernando Pérez-Parra, Adrián Ares-Luque, Nieves Téllez, Joaquín Arzalluz-Luque, Federico Iglesias, Virginia Casado-Ruiz, Alberto José Castellano-Vicente, Laura Borrega, Victoria Galán, Luis A Rodríguez de Antonio, Carlos Romero, Raquel García-Rodríguez, Antonio Tomás Cano-Orgaz, José Luis Sánchez-Menoyo, Domingo Pérez-Ruiz, Fuencisla Gutiérrez-Martin, Luis Hernández-Echevarría, Virginia Meca-Lallana

Background: Current literature and a real-world study suggest that diroximel fumarate (DRF) is safer than dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). However, no real-world study to date has significantly addressed the efficacy of this treatment.

Objectives: This study aims to elucidate the safety, tolerability, and efficacy of DRF in a real-world setting, utilizing data from a Spanish national registry of patients commencing DRF therapy post-market introduction.

Methods: In this multicenter, prospective observational study, data were collected from MS patients who initiated DRF treatment. The study monitored demographic and clinical characteristics, safety outcomes (including adverse events, reasons for discontinuation, and lymphocyte counts), and efficacy outcomes (radiological and clinical activity).

Results: A total of 195 MS patients across 26 neurological departments were included, predominantly female (79.5%), with a mean age of 42.17 years, and a mean duration of treatment with DRF of 6.3 months. Most patients (70.3%) reported no adverse events, while gastrointestinal issues and flushing were the most common adverse events observed. The majority of patients (84.6%) continued with DRF treatment, with tolerability issues being the primary reason for discontinuation. Efficacy analysis showed low relapse rates post-DRF initiation, with most patients exhibiting stable or improved Expanded Disability Status Scale scores and radiological assessments demonstrating minimal activity.

Conclusion: This comprehensive analysis provides valuable insights into the real-world application of DRF, confirming its safety and tolerability while offering preliminary evidence of its efficacy in managing MS.

背景:现有文献和一项实际研究表明,在治疗多发性硬化症(MS)时,富马酸双羟萘胺(DRF)比富马酸二甲酯(DMF)更安全。然而,迄今为止还没有一项真实世界研究对该疗法的疗效进行过深入探讨:本研究旨在阐明 DRF 在真实世界环境中的安全性、耐受性和疗效,利用的数据来自西班牙国家登记处,该登记处登记了 DRF 上市后开始治疗的患者:在这项多中心前瞻性观察研究中,收集了开始接受 DRF 治疗的多发性硬化症患者的数据。研究监测了人口统计学和临床特征、安全性结果(包括不良事件、停药原因和淋巴细胞计数)以及疗效结果(放射学和临床活动):26个神经科共纳入195名多发性硬化症患者,其中以女性为主(79.5%),平均年龄为42.17岁,接受DRF治疗的平均时间为6.3个月。大多数患者(70.3%)未报告不良反应,而胃肠道问题和潮红是最常见的不良反应。大多数患者(84.6%)继续接受 DRF 治疗,耐受性问题是患者中断治疗的主要原因。疗效分析表明,DRF治疗后的复发率较低,大多数患者的残疾状况扩展量表评分稳定或有所改善,放射学评估显示活动性极小:这项综合分析为 DRF 在现实世界中的应用提供了有价值的见解,证实了 DRF 的安全性和耐受性,同时也为 DRF 治疗多发性硬化症的疗效提供了初步证据。
{"title":"Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.","authors":"Clara Aguirre, Ana Alonso-Torres, Eduardo Agüera, José Manuel García-Domínguez, Paloma Montero-Escribano, Vicente González-Quintanilla, Lucienne Costa-Frossard, Celia Oreja-Guevara, Virginia Reyes-Garrido, Ana Belén Caminero-Rodríguez, Javier Riancho, Octavio Sánchez, Lucía Forero, Fernando Pérez-Parra, Adrián Ares-Luque, Nieves Téllez, Joaquín Arzalluz-Luque, Federico Iglesias, Virginia Casado-Ruiz, Alberto José Castellano-Vicente, Laura Borrega, Victoria Galán, Luis A Rodríguez de Antonio, Carlos Romero, Raquel García-Rodríguez, Antonio Tomás Cano-Orgaz, José Luis Sánchez-Menoyo, Domingo Pérez-Ruiz, Fuencisla Gutiérrez-Martin, Luis Hernández-Echevarría, Virginia Meca-Lallana","doi":"10.1007/s40261-024-01397-5","DOIUrl":"https://doi.org/10.1007/s40261-024-01397-5","url":null,"abstract":"<p><strong>Background: </strong>Current literature and a real-world study suggest that diroximel fumarate (DRF) is safer than dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). However, no real-world study to date has significantly addressed the efficacy of this treatment.</p><p><strong>Objectives: </strong>This study aims to elucidate the safety, tolerability, and efficacy of DRF in a real-world setting, utilizing data from a Spanish national registry of patients commencing DRF therapy post-market introduction.</p><p><strong>Methods: </strong>In this multicenter, prospective observational study, data were collected from MS patients who initiated DRF treatment. The study monitored demographic and clinical characteristics, safety outcomes (including adverse events, reasons for discontinuation, and lymphocyte counts), and efficacy outcomes (radiological and clinical activity).</p><p><strong>Results: </strong>A total of 195 MS patients across 26 neurological departments were included, predominantly female (79.5%), with a mean age of 42.17 years, and a mean duration of treatment with DRF of 6.3 months. Most patients (70.3%) reported no adverse events, while gastrointestinal issues and flushing were the most common adverse events observed. The majority of patients (84.6%) continued with DRF treatment, with tolerability issues being the primary reason for discontinuation. Efficacy analysis showed low relapse rates post-DRF initiation, with most patients exhibiting stable or improved Expanded Disability Status Scale scores and radiological assessments demonstrating minimal activity.</p><p><strong>Conclusion: </strong>This comprehensive analysis provides valuable insights into the real-world application of DRF, confirming its safety and tolerability while offering preliminary evidence of its efficacy in managing MS.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial. 基于 EMPA-KIDNEY 临床试验的 Empagliflozin (JARDIANCE®) 治疗法国慢性肾病患者的成本效益。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-24 DOI: 10.1007/s40261-024-01398-4
Harinala Groyer, Romain Supiot, Jean Tardu, Nicolas Virely, Marine Sivignon, Denis San, Pierre Lévy, Anastasia Ustyugova, Ziad A Massy

Background and objective: The efficacy and safety of empagliflozin in the treatment of chronic kidney disease (CKD) were demonstrated in the EMPA-KIDNEY trial, which showed a 28% reduction in combined risks of kidney disease or death from cardiovascular causes (hazard ratio, 0.72; 95% confidence interval, 0.64-0.82; p < 0.001) compared with placebo. Based on these results, the present study aimed to assess the cost-effectiveness of empagliflozin + standard of care (SoC) compared with SoC alone in the treatment of CKD in France.

Methods: A Markov state microsimulation model was adapted to compare the health and economic outcomes in France, considering a healthcare system perspective, in patients treated with empagliflozin in addition to SoC versus patients treated with SoC alone. The model simulated the intention-to-treat population of the trial, transitioning between 18 mutually exclusive and collectively exhaustive health states defined based on the Kidney Disease: Improving Global Outcomes classification. For each arm, the model estimated (over a 25-year time horizon) the number of events and deaths, and the costs associated with these events, to calculate the incremental cost-effectiveness ratio. The resources used were derived using French authorities reports, literature, and French CKD guidelines. Both economic and health outcomes were discounted at a 2.5% annual rate according to French guidelines.

Results: The model predicted that using empagliflozin + SoC to treat patients with CKD would prevent CKD-related complications and deaths associated with a cardiovascular event or all-cause deaths while in kidney replacement therapy, resulting on average in a discounted gain of 1.29 years in overall survival (9.48 years vs. 8.19 with SoC alone). Empagliflozin costs (treatment, events, and disease management) were completely offset by the cost savings from avoided kidney failure events. Overall, empagliflozin + SoC would be more effective and less costly than SoC alone and would therefore be the dominant treatment strategy. The sensitivity analyses conducted support the results' robustness in showing the dominance of empagliflozin + SoC over SoC alone.

Conclusions: The base-case results indicate that empagliflozin + SoC is a dominant strategy compared with the current SoC for the management of CKD in France. Empagliflozin + SoC would have a positive impact on patients with CKD by slowing CKD progression and leading to the prevention of kidney failure events on top of all-stages CKD complications.

背景和目的:EMPA-KIDNEY试验显示,与安慰剂相比,empagliflozin治疗慢性肾脏病(CKD)的疗效和安全性降低了28%(危险比为0.72;95%置信区间为0.64-0.82;P < 0.001)。基于这些结果,本研究旨在评估在法国治疗慢性肾脏病时,empagliflozin+标准疗法(SoC)与单独使用标准疗法相比的成本效益:采用马尔可夫状态微观模拟模型,从医疗保健系统的角度出发,比较在法国接受empagliflozin+SoC治疗的患者与仅接受SoC治疗的患者的健康和经济结果。该模型模拟了试验中的意向治疗人群,在根据肾脏疾病分类界定的 18 种相互排斥且共同详尽的健康状态之间转换:改善全球疗效》分类法定义的 18 种相互排斥且共同详尽的健康状态之间转换。对于每个治疗组,该模型(在 25 年的时间跨度内)估算了事件数和死亡数,以及与这些事件相关的成本,从而计算出增量成本效益比。所使用的资源来自法国权威报告、文献和法国慢性肾脏病指南。根据法国指南,经济和健康结果均按2.5%的年贴现率进行贴现:该模型预测,使用恩格列净+SoC治疗CKD患者可预防CKD相关并发症、心血管事件相关死亡或肾脏替代治疗期间的全因死亡,平均可使总生存期折现延长1.29年(9.48年与单独使用SoC的8.19年相比)。因避免肾衰竭事件而节省的成本完全抵消了恩格列净的成本(治疗、事件和疾病管理)。总体而言,与单独使用 SoC 相比,恩格列净 + SoC 的疗效更好、成本更低,因此是最主要的治疗策略。所进行的敏感性分析支持了结果的稳健性,显示了恩格列净+SoC比单独使用SoC更有优势:基础研究结果表明,在法国,与目前的SoC相比,empagliflozin + SoC是治疗CKD的主要策略。Empagliflozin + SoC 将对慢性肾功能衰竭患者产生积极影响,因为它能减缓慢性肾功能衰竭的进展,并在所有阶段的慢性肾功能衰竭并发症基础上预防肾衰竭事件的发生。
{"title":"Cost-Effectiveness of Empagliflozin (JARDIANCE<sup>®</sup>) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial.","authors":"Harinala Groyer, Romain Supiot, Jean Tardu, Nicolas Virely, Marine Sivignon, Denis San, Pierre Lévy, Anastasia Ustyugova, Ziad A Massy","doi":"10.1007/s40261-024-01398-4","DOIUrl":"https://doi.org/10.1007/s40261-024-01398-4","url":null,"abstract":"<p><strong>Background and objective: </strong>The efficacy and safety of empagliflozin in the treatment of chronic kidney disease (CKD) were demonstrated in the EMPA-KIDNEY trial, which showed a 28% reduction in combined risks of kidney disease or death from cardiovascular causes (hazard ratio, 0.72; 95% confidence interval, 0.64-0.82; p < 0.001) compared with placebo. Based on these results, the present study aimed to assess the cost-effectiveness of empagliflozin + standard of care (SoC) compared with SoC alone in the treatment of CKD in France.</p><p><strong>Methods: </strong>A Markov state microsimulation model was adapted to compare the health and economic outcomes in France, considering a healthcare system perspective, in patients treated with empagliflozin in addition to SoC versus patients treated with SoC alone. The model simulated the intention-to-treat population of the trial, transitioning between 18 mutually exclusive and collectively exhaustive health states defined based on the Kidney Disease: Improving Global Outcomes classification. For each arm, the model estimated (over a 25-year time horizon) the number of events and deaths, and the costs associated with these events, to calculate the incremental cost-effectiveness ratio. The resources used were derived using French authorities reports, literature, and French CKD guidelines. Both economic and health outcomes were discounted at a 2.5% annual rate according to French guidelines.</p><p><strong>Results: </strong>The model predicted that using empagliflozin + SoC to treat patients with CKD would prevent CKD-related complications and deaths associated with a cardiovascular event or all-cause deaths while in kidney replacement therapy, resulting on average in a discounted gain of 1.29 years in overall survival (9.48 years vs. 8.19 with SoC alone). Empagliflozin costs (treatment, events, and disease management) were completely offset by the cost savings from avoided kidney failure events. Overall, empagliflozin + SoC would be more effective and less costly than SoC alone and would therefore be the dominant treatment strategy. The sensitivity analyses conducted support the results' robustness in showing the dominance of empagliflozin + SoC over SoC alone.</p><p><strong>Conclusions: </strong>The base-case results indicate that empagliflozin + SoC is a dominant strategy compared with the current SoC for the management of CKD in France. Empagliflozin + SoC would have a positive impact on patients with CKD by slowing CKD progression and leading to the prevention of kidney failure events on top of all-stages CKD complications.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database. 糖尿病和心力衰竭患者使用钠-葡萄糖转运体 2 抑制剂的不良事件特征差异:利用日本药物不良事件报告数据库进行的分析。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-10-14 DOI: 10.1007/s40261-024-01394-8
Toshiaki Sakamoto, Hirotaka Miyamoto, Junya Hashizume, Hayato Akamatsu, Tomoaki Akagi, Yukinobu Kodama, Hirofumi Hamano, Yoshito Zamami, Kaname Ohyama

Background and objectives: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently become a standard treatment for heart failure and renal failure. The number of patients using these drugs is expected to increase further. However, no adverse drug event profiles have been published for the use of SGLT2i in patients without diabetes. To analyze and clarify the differences in adverse event profiles associated with the use of SGLT2i in patients with diabetes or heart failure using the Japanese Adverse Drug Event Report (JADER) database, a Japanese reporting system for adverse events.

Methods: The JADER database, containing reports submitted between April 2004 and January 2024, was used. Our study focused on patients with diabetes or heart failure, analyzing adverse events associated with empagliflozin and dapagliflozin. The reporting odds ratio (ROR) and 95% confidence interval (CI) were calculated for signal detection.

Results: We identified risks of adverse drug events such as ketoacidosis, urinary tract infection, dehydration, and acidosis in both patient groups. However, the risks of cerebral infarction and ischemic heart disease were identified only in patients with diabetes, while risks of renal dysfunction, hypoglycemia, and sepsis were identified only in those with heart failure.

Conclusion: Adverse events should be managed appropriately for patients using SGLT2i, as the adverse event profiles differ between those with diabetes and those with heart failure. Understanding these differences is crucial for improving patient safety and optimizing treatment outcomes.

背景和目的:钠-葡萄糖共转运体 2 抑制剂(SGLT2i)最近已成为治疗心力衰竭和肾功能衰竭的标准药物。预计使用这些药物的患者人数将进一步增加。然而,目前尚未公布在非糖尿病患者中使用 SGLT2i 的药物不良事件概况。目的是利用日本的不良事件报告系统--日本药物不良事件报告(JADER)数据库,分析并阐明糖尿病或心力衰竭患者使用 SGLT2i 后的不良事件特征差异:研究使用的 JADER 数据库包含 2004 年 4 月至 2024 年 1 月期间提交的报告。我们的研究主要针对糖尿病或心力衰竭患者,分析了与恩格列净和达帕格列净相关的不良事件。为检测信号,计算了报告几率比(ROR)和95%置信区间(CI):我们在两组患者中均发现了酮症酸中毒、尿路感染、脱水和酸中毒等药物不良事件的风险。然而,仅在糖尿病患者中发现了脑梗塞和缺血性心脏病的风险,而仅在心力衰竭患者中发现了肾功能障碍、低血糖和败血症的风险:使用 SGLT2i 的患者应适当控制不良事件,因为糖尿病患者和心力衰竭患者的不良事件特征有所不同。了解这些差异对于提高患者安全性和优化治疗效果至关重要。
{"title":"Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database.","authors":"Toshiaki Sakamoto, Hirotaka Miyamoto, Junya Hashizume, Hayato Akamatsu, Tomoaki Akagi, Yukinobu Kodama, Hirofumi Hamano, Yoshito Zamami, Kaname Ohyama","doi":"10.1007/s40261-024-01394-8","DOIUrl":"10.1007/s40261-024-01394-8","url":null,"abstract":"<p><strong>Background and objectives: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently become a standard treatment for heart failure and renal failure. The number of patients using these drugs is expected to increase further. However, no adverse drug event profiles have been published for the use of SGLT2i in patients without diabetes. To analyze and clarify the differences in adverse event profiles associated with the use of SGLT2i in patients with diabetes or heart failure using the Japanese Adverse Drug Event Report (JADER) database, a Japanese reporting system for adverse events.</p><p><strong>Methods: </strong>The JADER database, containing reports submitted between April 2004 and January 2024, was used. Our study focused on patients with diabetes or heart failure, analyzing adverse events associated with empagliflozin and dapagliflozin. The reporting odds ratio (ROR) and 95% confidence interval (CI) were calculated for signal detection.</p><p><strong>Results: </strong>We identified risks of adverse drug events such as ketoacidosis, urinary tract infection, dehydration, and acidosis in both patient groups. However, the risks of cerebral infarction and ischemic heart disease were identified only in patients with diabetes, while risks of renal dysfunction, hypoglycemia, and sepsis were identified only in those with heart failure.</p><p><strong>Conclusion: </strong>Adverse events should be managed appropriately for patients using SGLT2i, as the adverse event profiles differ between those with diabetes and those with heart failure. Understanding these differences is crucial for improving patient safety and optimizing treatment outcomes.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan. 在日本,Atezolizumab 与 Durvalumab 作为广泛病变小细胞肺癌患者一线化疗联合疗法的成本效益比较。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-09-21 DOI: 10.1007/s40261-024-01383-x
Munenobu Kashiwa, Miho Tsukada, Ryo Matsushita

BACKGROUND AND OBJECTIVE: Recent trials have shown that immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, in combination with chemotherapy, are effective in treating extensive-disease small-cell lung cancer (ED-SCLC). However, owing to the expensiveness of ICIs, monetary issues arise. The cost-effectiveness of ICI combination treatment with carboplatin plus etoposide (CE) as first-line therapy for patients with ED-SCLC was examined to aid public health policy in Japan.

Methods: IMpower 133 and CASPIAN data were used to create a partitioned survival model. Medical expenses and quality-adjusted life years (QALYs) were considered. The analysis period, discount rate, and threshold were set at 20 years, 2%, and 15 million Japanese yen (JPY) [114,068 US dollars (USD)] per QALY, respectively. The incremental cost-effectiveness ratio (ICER) was calculated by gathering reasonable parameters from published reports and combining the costs and effects using parametric models. Monte Carlo simulations, scenario analysis, and one-way sensitivity analyses were employed to quantify uncertainty.

Results: After comparing atezolizumab plus CE (ACE) and durvalumab plus CE (DCE) with CE, it was found that the ICERs exceeded the threshold at 35,048,299 JPY (266,527 USD) and 36,665,583 JPY (278,826 USD) per QALY, respectively. For one-way sensitivity and scenario assessments, the ICERs exceeded the threshold, even with considerably adjusted parameters. For the probabilistic sensitivity analyses, there was no probability that the ICER of the ICI combination treatment with chemotherapy would fall below the threshold.

Conclusion: ACE and DCE were not cost-effective compared with CE as first-line therapy for ED-SCLC in Japan. Both these therapies exhibited high ICERs.

背景和目的:最近的试验表明,免疫检查点抑制剂(ICIs)、atezolizumab 和 durvalumab 与化疗联合使用可有效治疗广泛病变小细胞肺癌(ED-SCLC)。然而,由于 ICIs 价格昂贵,因此出现了资金问题。为了帮助日本制定公共卫生政策,我们研究了 ICI 与卡铂加依托泊苷(CE)联合治疗作为 ED-SCLC 患者一线疗法的成本效益:方法:使用 IMpower 133 和 CASPIAN 数据创建了一个分区生存模型。方法:使用 IMpower 133 和 CASPIAN 数据创建了分区生存模型,并考虑了医疗费用和质量调整生命年 (QALY)。分析期限、贴现率和阈值分别定为 20 年、2% 和每 QALY 1,500 万日元 [114,068 美元]。增量成本效益比 (ICER) 的计算方法是从已发表的报告中收集合理的参数,并使用参数模型将成本和效果结合起来。采用蒙特卡罗模拟、情景分析和单向敏感性分析来量化不确定性:结果:在比较了阿特珠单抗+CE(ACE)和德伐卢单抗+CE(DCE)与CE后,发现ICER超过了阈值,分别为每QALY 35,048,299日元(266,527美元)和36,665,583日元(278,826美元)。在单向敏感性和情景评估中,即使对参数进行了大幅调整,ICER 也超过了阈值。在概率敏感性分析中,ICI联合化疗的ICER不可能低于阈值:结论:在日本,作为 ED-SCLC 的一线疗法,ACE 和 DCE 与 CE 相比不具成本效益。这两种疗法的 ICER 都很高。
{"title":"Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan.","authors":"Munenobu Kashiwa, Miho Tsukada, Ryo Matsushita","doi":"10.1007/s40261-024-01383-x","DOIUrl":"10.1007/s40261-024-01383-x","url":null,"abstract":"<p><p>BACKGROUND AND OBJECTIVE: Recent trials have shown that immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, in combination with chemotherapy, are effective in treating extensive-disease small-cell lung cancer (ED-SCLC). However, owing to the expensiveness of ICIs, monetary issues arise. The cost-effectiveness of ICI combination treatment with carboplatin plus etoposide (CE) as first-line therapy for patients with ED-SCLC was examined to aid public health policy in Japan.</p><p><strong>Methods: </strong>IMpower 133 and CASPIAN data were used to create a partitioned survival model. Medical expenses and quality-adjusted life years (QALYs) were considered. The analysis period, discount rate, and threshold were set at 20 years, 2%, and 15 million Japanese yen (JPY) [114,068 US dollars (USD)] per QALY, respectively. The incremental cost-effectiveness ratio (ICER) was calculated by gathering reasonable parameters from published reports and combining the costs and effects using parametric models. Monte Carlo simulations, scenario analysis, and one-way sensitivity analyses were employed to quantify uncertainty.</p><p><strong>Results: </strong>After comparing atezolizumab plus CE (ACE) and durvalumab plus CE (DCE) with CE, it was found that the ICERs exceeded the threshold at 35,048,299 JPY (266,527 USD) and 36,665,583 JPY (278,826 USD) per QALY, respectively. For one-way sensitivity and scenario assessments, the ICERs exceeded the threshold, even with considerably adjusted parameters. For the probabilistic sensitivity analyses, there was no probability that the ICER of the ICI combination treatment with chemotherapy would fall below the threshold.</p><p><strong>Conclusion: </strong>ACE and DCE were not cost-effective compared with CE as first-line therapy for ED-SCLC in Japan. Both these therapies exhibited high ICERs.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System. 乳腺癌患者中与细胞周期蛋白依赖性激酶 4/6 抑制剂相关的神经和精神不良事件:通过 FDA 不良事件报告系统进行的药物警戒研究的启示。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-10-11 DOI: 10.1007/s40261-024-01396-6
Zicheng Yu, Mengying Guan, Xiaolan Liao

Background and objective: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have revolutionised cancer therapy, particularly breast cancer therapy. However, concerns about their potential to cause neurological and psychiatric adverse events (AEs) have emerged, and these concerns remain underexplored. This study aimed to investigate the signals related to neurological and psychiatric AEs associated with CDK4/6 inhibitor use.

Methods: A retrospective study was performed to analyse reports of AEs associated with the use of CDK4/6 inhibitors (abemaciclib, ribociclib and palbociclib) from the first quarter of 2015 to the fourth quarter of 2023 on the basis of the FDA Adverse Event Reporting System (FAERS). Both the reporting odds ratio (ROR) and the multi-item gamma Poisson shrinker (MGPS) were used for signal detection. The timing of events was assessed with the Weibull shape parameter (WSP). The management, analysis and presentation of the data were performed via Python (version 3.8) and R software (version 4.3.2).

Results: A total of 19,001 AE reports in which CDK4/6 inhibitors were identified as the 'primary suspect drug' were included in this study. These events were predominantly observed in patients aged 65 to 85 years. Through an ROR analysis, 85 positive signals for neurological and psychiatric AEs associated with CDK4/6 inhibitors were identified. The MGPS method revealed 61 positive AE signals for neurological and psychiatric AEs associated with CDK4/6 inhibitors. A total of 34 positive AE signals were identified by both the ROR and MGPS analyses. The WSP indicated that the onset times for AEs associated with all three CDK4/6 inhibitors tended to be early in drug therapy, suggesting a propensity for early failure type.

Conclusion: The present study revealed neurological and psychiatric AEs associated with CDK4/6 inhibitors that often occur early in treatment. Significant signals include spinal cord herniation and cerebral microangiopathy. Close monitoring of these AEs is crucial. Further studies are necessary to verify the connection between CDK4/6 inhibitors and neurological and psychiatric AEs.

背景和目的:细胞周期蛋白依赖性激酶 4/6 (CDK4/6) 抑制剂为癌症治疗,尤其是乳腺癌治疗带来了革命性的变化。然而,人们开始担心它们可能会导致神经和精神不良事件(AEs),而这些问题仍未得到充分探讨。本研究旨在调查与使用CDK4/6抑制剂相关的神经和精神不良事件信号:根据FDA不良事件报告系统(FAERS),对2015年第一季度至2023年第四季度与使用CDK4/6抑制剂(abemaciclib、ribociclib和palbociclib)相关的AEs报告进行了回顾性分析。信号检测采用了报告几率比(ROR)和多项目伽马泊松收缩器(MGPS)。事件发生的时间是用魏布勒形状参数(WSP)来评估的。数据的管理、分析和展示通过 Python(3.8 版)和 R 软件(4.3.2 版)进行:本研究共纳入了 19,001 份以 CDK4/6 抑制剂为 "主要可疑药物 "的 AE 报告。这些事件主要发生在 65 至 85 岁的患者身上。通过ROR分析,确定了85个与CDK4/6抑制剂相关的神经和精神AE阳性信号。MGPS方法发现了61个与CDK4/6抑制剂相关的神经系统和精神系统AE阳性信号。ROR和MGPS分析共发现了34个阳性AE信号。WSP表明,与所有三种CDK4/6抑制剂相关的AE的发病时间往往在药物治疗的早期,这表明存在早期失败类型的倾向:本研究揭示了与 CDK4/6 抑制剂相关的神经系统和精神系统 AEs,这些 AEs 通常发生在治疗早期。重要信号包括脊髓疝和脑微血管病。密切监测这些不良反应至关重要。有必要开展进一步研究,以验证CDK4/6抑制剂与神经和精神AEs之间的联系。
{"title":"Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.","authors":"Zicheng Yu, Mengying Guan, Xiaolan Liao","doi":"10.1007/s40261-024-01396-6","DOIUrl":"10.1007/s40261-024-01396-6","url":null,"abstract":"<p><strong>Background and objective: </strong>Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have revolutionised cancer therapy, particularly breast cancer therapy. However, concerns about their potential to cause neurological and psychiatric adverse events (AEs) have emerged, and these concerns remain underexplored. This study aimed to investigate the signals related to neurological and psychiatric AEs associated with CDK4/6 inhibitor use.</p><p><strong>Methods: </strong>A retrospective study was performed to analyse reports of AEs associated with the use of CDK4/6 inhibitors (abemaciclib, ribociclib and palbociclib) from the first quarter of 2015 to the fourth quarter of 2023 on the basis of the FDA Adverse Event Reporting System (FAERS). Both the reporting odds ratio (ROR) and the multi-item gamma Poisson shrinker (MGPS) were used for signal detection. The timing of events was assessed with the Weibull shape parameter (WSP). The management, analysis and presentation of the data were performed via Python (version 3.8) and R software (version 4.3.2).</p><p><strong>Results: </strong>A total of 19,001 AE reports in which CDK4/6 inhibitors were identified as the 'primary suspect drug' were included in this study. These events were predominantly observed in patients aged 65 to 85 years. Through an ROR analysis, 85 positive signals for neurological and psychiatric AEs associated with CDK4/6 inhibitors were identified. The MGPS method revealed 61 positive AE signals for neurological and psychiatric AEs associated with CDK4/6 inhibitors. A total of 34 positive AE signals were identified by both the ROR and MGPS analyses. The WSP indicated that the onset times for AEs associated with all three CDK4/6 inhibitors tended to be early in drug therapy, suggesting a propensity for early failure type.</p><p><strong>Conclusion: </strong>The present study revealed neurological and psychiatric AEs associated with CDK4/6 inhibitors that often occur early in treatment. Significant signals include spinal cord herniation and cerebral microangiopathy. Close monitoring of these AEs is crucial. Further studies are necessary to verify the connection between CDK4/6 inhibitors and neurological and psychiatric AEs.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcipotriol and 5-Fluorouracil Combination Therapy for the Treatment of Actinic Keratosis in the Clinic: A Review Article. 钙泊三醇和 5-氟尿嘧啶联合疗法用于治疗临床上的日光性角化病:综述文章。
IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-09-28 DOI: 10.1007/s40261-024-01392-w
Anna H Dlott, Sara A Spencer, Anthony J Di Pasqua

This review examines the pharmacology, efficacy and safety, dosage and administration, and place in therapy of the combination of 5-fluorouracil (5-FU) and calcipotriol for the treatment of actinic keratosis. Currently, 5% 5-FU topical cream is approved for actinic keratosis treatment, while calcipotriol is indicated for plaque psoriasis in adults. The typical administration of 5-FU involves topical application twice daily for up to 4 weeks, whereas calcipotriol is applied in a thin layer once or twice daily as directed by a physician. Adverse effects of 5-FU are primarily localized, including skin irritation, ulceration, pruritus, erythema, crusting, and eczematous reactions due to minimal systemic absorption. Calcipotriol may cause burning, itching, and skin irritation. This review details clinical trials that investigate the innovative approach of combining topical 5-FU with calcipotriol for actinic keratosis treatment, highlighting the significant outcomes. Notably, the clinical trials indicate that all participants experienced either a reduction in lesion size or complete lesion clearance, with minimal adverse effects impacting treatment success. The combination of 5-FU and calcipotriol effectively treats actinic keratosis by enhancing the immune response and targeting cell overgrowth, while reducing local site reactions and the lengthy treatment time often associated with existing therapies.

本综述探讨了 5-氟尿嘧啶(5-FU)和钙泊三醇联合治疗光化性角化病的药理、疗效和安全性、剂量和用法以及在治疗中的地位。目前,5% 5-FU 外用乳膏已被批准用于治疗光化性角化病,而钙泊三醇则适用于成人斑块状银屑病。5-FU 的典型用法是每天两次局部涂抹,最长持续 4 周;而钙泊三醇则是在医生指导下每天涂抹一到两次薄层。5-FU 的不良反应主要是局部的,包括皮肤刺激、溃疡、瘙痒、红斑、结痂和湿疹反应,因为全身吸收极少。钙泊三醇可能会引起烧灼感、瘙痒和皮肤过敏。本综述详细介绍了研究将局部 5-FU 与钙泊三醇联合用于治疗光化性角化病这一创新方法的临床试验,并重点介绍了其显著疗效。值得注意的是,临床试验表明,所有参与者的皮损面积都有所缩小或完全清除,对治疗成功的不良影响极小。5-FU 和钙泊三醇的组合能增强免疫反应,针对细胞过度生长,从而有效治疗光化性角化病,同时减少局部反应,缩短现有疗法通常需要的漫长治疗时间。
{"title":"Calcipotriol and 5-Fluorouracil Combination Therapy for the Treatment of Actinic Keratosis in the Clinic: A Review Article.","authors":"Anna H Dlott, Sara A Spencer, Anthony J Di Pasqua","doi":"10.1007/s40261-024-01392-w","DOIUrl":"10.1007/s40261-024-01392-w","url":null,"abstract":"<p><p>This review examines the pharmacology, efficacy and safety, dosage and administration, and place in therapy of the combination of 5-fluorouracil (5-FU) and calcipotriol for the treatment of actinic keratosis. Currently, 5% 5-FU topical cream is approved for actinic keratosis treatment, while calcipotriol is indicated for plaque psoriasis in adults. The typical administration of 5-FU involves topical application twice daily for up to 4 weeks, whereas calcipotriol is applied in a thin layer once or twice daily as directed by a physician. Adverse effects of 5-FU are primarily localized, including skin irritation, ulceration, pruritus, erythema, crusting, and eczematous reactions due to minimal systemic absorption. Calcipotriol may cause burning, itching, and skin irritation. This review details clinical trials that investigate the innovative approach of combining topical 5-FU with calcipotriol for actinic keratosis treatment, highlighting the significant outcomes. Notably, the clinical trials indicate that all participants experienced either a reduction in lesion size or complete lesion clearance, with minimal adverse effects impacting treatment success. The combination of 5-FU and calcipotriol effectively treats actinic keratosis by enhancing the immune response and targeting cell overgrowth, while reducing local site reactions and the lengthy treatment time often associated with existing therapies.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Drug Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1